/ Lupin Trades Higher On The Bourses ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Friday, 27 October 2017



Lupin is currently trading at Rs. 1009.05, up by 11.95 points or 1.20% from its previous closing of Rs. 997.10 on the BSE.

The scrip opened at Rs. 1009.80 and has touched a high and low of Rs. 1019.90 and Rs. 999.00 respectively. So far 75,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1572.25 on 06-Feb-2017 and a 52 week low of Rs. 920.00 on 21-Aug-2017.

Last one week high and low of the scrip stood at Rs. 1056.00 and Rs. 991.15 respectively. The current market cap of the company is Rs. 45,592.00 crore.

The promoters holding in the company stood at 46.80%, while Institutions and Non-Institutions held 40.05% and 13.14% respectively.

Lupin has received final approval for its Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Concordia Pharmaceuticals Inc.'s Kapvay Extended-Release Tablets 0.1 mg.

Lupin's Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg is the AB rated generic equivalent of Concordia Pharmaceuticals Inc.'s Kapvay Extended-Release Tablets 0.1 mg. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications. As per IMS MAT Jun 2017, Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg had annual sales of around $66 million in the US.


Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717

0 comments: